MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacl.2025.04.200

Медицинская библиотека · Journal of clinical lipidology · 2025

Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels.

Kelly Michael S, Jeminiwa Ruth N, Gohar Fatima, Fanous Mario, Ramirez Pablo, Dixon Dave L

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Elevated lipoprotein(a) (Lp(a)) is a recognized independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular-related disorders. To mitigate the increased risk associated with elevated Lp(a), intensified treatment is recommended for modifiable ASCVD risk factors, such as hypertension, hyperglycemia, and dyslipidemia. However, limited evidence has assessed how clinicians are modifying lipid-lowering therapy in response to elevated Lp(a) levels.

OBJECTIVE

To evaluate changes to lipid-lowering therapy and assess which patient characteristics are associated with intensifying lipid-lowering medications.

METHODS

This retrospective, observational case-control study evaluated changes to lipid-lowering therapy in patients with elevated Lp(a) values from January 1, 2020, through May 31, 2024.

RESULTS

Of 1042 patients with an Lp(a) value of 30 mg/dL (75 nmol/L) or higher during our study period, 539 met full inclusion eligibility. Of the 539 patients, 120 (22.3%) had their lipid-lowering therapy modified within 30 days of the elevated Lp(a) result. The most common interventions were adding ezetimibe (33.3%) and intensifying statin therapy (32.5%). Elevated low-density lipoprotein cholesterol (LDL-C) was the most significant predictor of whether patients' lipid medications were modified, concordant with current recommendations for mitigating increased ASCVD risk associated with elevated Lp(a).

CONCLUSION

Intensification of lipid-lowering medication within 30 days occurred in less than one-quarter of patients with elevated Lp(a). Future studies are needed to determine if aggressive LDL-C lowering is superior to Lp(a)-lowering to prevent ASCVD events in patients with elevated Lp(a).

Для цитирования: Kelly Michael S, Jeminiwa Ruth N, Gohar Fatima, Fanous Mario, Ramirez Pablo, Dixon Dave L. Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels.. Journal of clinical lipidology. 2025. DOI: 10.1016/j.jacl.2025.04.200.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.